Pro-Pharmaceuticals, Inc. Collaborates With Chemwerth USA To Scale-up Production Of DAVANAT(R) For Initial Marketing Needs
Published: Feb 20, 2007
NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds, today announced it is collaborating with Chemwerth, Inc. to scale-up production of its lead drug candidate, DAVANAT® to 100 kilograms for initial marketing needs. DAVANAT® is a carbohydrate polymer composed of mannose and galactose (galactomannan). Chemwerth, Inc. is an Active Pharmaceutical Ingredient (API) development and supply company specializing in generic drugs that include oral, injectable, topical and veterinary products.